Ropes & Gray Leads Black Diamond Therapeutics In Licensing Deal With Servier
The collaboration will advance across multiple indications, including non-small cell lung cancer and solid tumors;
Ropes & Gray Leads Black Diamond Therapeutics In Licensing Deal With Servier
The collaboration will advance across multiple indications, including non-small cell lung cancer and solid tumors
American law firm Ropes & Gray has represented Black Diamond Therapeutics in a global licensing agreement with French pharmaceutical Servier.
It is to develop and commercialize BDTX-4933, a therapy designed to target RAS and RAF alterations in solid tumors. It will advance the asset across multiple indications, including non-small cell lung cancer and other solid tumors.
Black Diamond will receive an upfront payment of $70 million and is eligible for up to $710 million, along with tiered royalties on global net sales.
The Ropes & Gray team was led by Life Sciences Licensing Partner Abigail Gregor and IP Transactions Associate Esteban De La Torre. It included Litigation & Enforcement Partner Lisa Kaltenbrunner and Litigation & Enforcement Associate Vincenzo Volpe.
